QuidelOrtho (QDEL) Stock Price, News & Analysis

Company Overview

QuidelOrtho is a global diagnostics company formed through the merger of Quidel Corporation and Ortho Clinical Diagnostics. The combined entity develops, manufactures and markets a broad portfolio of rapid and high-throughput diagnostic solutions across immunoassay, molecular diagnostics and transfusion medicine. Its offerings span point-of-care platforms for acute care testing as well as large-scale automated systems designed for clinical laboratories and blood banks.

The company’s product range includes rapid antigen and antibody tests for infectious diseases, molecular assays utilizing nucleic acid amplification technology, and integrated immunodiagnostic analyzers. Notable platforms include the Sofia fluorescence immunoassay system, the Solana molecular diagnostics platform and the VITROS® family of high-volume immunoassay instruments. In transfusion diagnostics, QuidelOrtho provides blood-typing, antibody screening and donor management solutions aimed at improving safety and efficiency in blood centers and hospital transfusion services.

QuidelOrtho brings together decades of diagnostic expertise. Quidel was founded in 1979 with a focus on rapid immunoassays, while Ortho Clinical Diagnostics traces its heritage to the diagnostic divisions of Johnson & Johnson dating back to the mid-20th century. In late 2022, the two businesses combined to expand their global reach, enhance R&D capabilities and streamline manufacturing operations. The company is headquartered in San Diego, California, with additional research, development and production facilities across North America, Europe and Asia.

Led by President and Chief Executive Officer Douglas Bryant, QuidelOrtho serves hospitals, reference laboratories, physician offices, public health agencies and blood banks worldwide. The company emphasizes innovation through ongoing investment in assay development, digital connectivity and data analytics to enable faster decision-making and support patient care initiatives across diverse healthcare settings.

Key Stats

• Today's Range: $27.48 to $28.84
• 50-Day Range: $22.81 to $31.57
• 52-Week Range: $22.05 to $49.45
• Volume: 937,452 shs
• Average Volume: 1.32 million shs
• Market Capitalization: $1.87 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $42.17
• Consensus Rating: Hold

QuidelOrtho Stock Analysis - MarketRank™

QuidelOrtho scored higher than 87% of companies evaluated by MarketBeat, and ranked 142nd out of 941 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.2 / 5
• Analyst Rating: Hold

Consensus Rating

QuidelOrtho has received a consensus rating of Hold. The company's average rating score is 2.43, and is based on 4 buy ratings, 2 hold ratings, and 1 sell rating.

Amount of Analyst Coverage

QuidelOrtho has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 39.57%

Earnings Growth

Earnings for QuidelOrtho are expected to grow by 39.57% in the coming year, from $2.30 to $3.21 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of QuidelOrtho is -4.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of QuidelOrtho is -4.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

QuidelOrtho has a P/B Ratio of 0.67. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

10.72% of the outstanding shares of QuidelOrtho have been sold short.

Short Interest Ratio / Days to Cover

QuidelOrtho has a short interest ratio ("days to cover") of 5.

Change versus previous month

Short interest in QuidelOrtho has recently increased by 10.47%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

QuidelOrtho does not currently pay a dividend.

Dividend Growth

QuidelOrtho does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 3.8 / 5
• Environmental Score: -2.61

Percentage of Shares Shorted

10.72% of the outstanding shares of QuidelOrtho have been sold short.

Short Interest Ratio / Days to Cover

QuidelOrtho has a short interest ratio ("days to cover") of 5.

Change versus previous month

Short interest in QuidelOrtho has recently increased by 10.47%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.1 / 5
• News Sentiment: 1.57

News Sentiment

QuidelOrtho has a news sentiment score of 1.57. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.96 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for QuidelOrtho this week, compared to 7 articles on an average week.

Search Interest

2 people have searched for QDEL on MarketBeat in the last 30 days.

MarketBeat Follows

Only 1 people have added QuidelOrtho to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, QuidelOrtho insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 0.79% of the stock of QuidelOrtho is held by insiders.

Percentage Held by Institutions

99.00% of the stock of QuidelOrtho is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

QDEL Stock Analysis - Frequently Asked Questions

How have QDEL shares performed this year?

QuidelOrtho's stock was trading at $44.55 at the beginning of 2025. Since then, QDEL stock has decreased by 38.0% and is now trading at $27.61.

How were QuidelOrtho's earnings last quarter?

QuidelOrtho Corporation (NASDAQ:QDEL) released its quarterly earnings results on Tuesday, August, 5th. The company reported $0.12 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.01 by $0.11. The company's revenue for the quarter was down 3.6% on a year-over-year basis.
Read the conference call transcript.

Who are QuidelOrtho's major shareholders?

QuidelOrtho's top institutional shareholders include Rubric Capital Management LP (6.83%), State Street Corp (3.98%), American Century Companies Inc. (2.82%) and AQR Capital Management LLC (2.68%). Insiders that own company stock include Brian J Blaser, Joseph M Busky and Carlyle Group Inc.
View institutional ownership trends.

How do I buy shares of QuidelOrtho?

Shares of QDEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of QuidelOrtho own?

Based on aggregate information from My MarketBeat watchlists, some other companies that QuidelOrtho investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), PayPal (PYPL), Salesforce (CRM) and CrowdStrike (CRWD).

Company Calendar

• Last Earnings: 8/05/2025
• Today: 9/03/2025
• Next Earnings (Estimated): 11/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED PRODUCTS
• Sub-Industry: Health Care Supplies
• Current Symbol: NASDAQ:QDEL
• CIK: 353569
• Web: www.quidel.com
• Phone: (800) 874-1517
• Fax: 858-453-4338
• Employees: 6,600
• Year Founded: 1979

Price Target and Rating

• Average Price Target for QuidelOrtho: $42.17
• High Price Target: $61.00
• Low Price Target: $25.00
• Potential Upside/Downside: +51.0%
• Consensus Rating: Hold
• Rating Score (0-4): 2.43
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): ($6.54)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 12.14
• P/E Growth: N/A
• Net Income: -$2.05 billion
• Net Margins: -16.10%
• Pretax Margin: -14.89%
• Return on Equity: 5.29%
• Return on Assets: 2.43%

Debt

• Debt-to-Equity Ratio: 0.74
• Current Ratio: 1.12
• Quick Ratio: 0.62

Sales & Book Value

• Annual Sales: $2.78 billion
• Price / Sales: 0.68
• Cash Flow: $34.47 per share
• Price / Cash Flow: 0.81
• Book Value: $41.13 per share
• Price / Book: 0.68

Miscellaneous

• Outstanding Shares: 67,900,000
• Free Float: 67,364,000
• Market Cap: $1.90 billion
• Optionable: Optionable
• Beta: 0.14